In the second part of our chat with Bright SCIdea finalist Team Eolic Wall, we found out how they prepared for their presentation and judges’ questions, and what’s next for their innovative wind turbine technology.
The road from Eureka moment to finished product is paved with peril. Team Eolic Wall’s idea for small, modular wind turbines that use magnetic levitation to harness more power than existing turbines could bring wind power generation into our very homes. But bringing a groundbreaking product to market is not just about mastering the science. It must make business sense too.
As with the other Bright SCIdea hopefuls, Team Eolic Wall received free training from SCI in the form of online tutorials from experienced professionals including modules on structuring a business, financial modelling, branding, and marketing.
After completing the training, Eolic Wall rose to meet the challenge. The team qualified for the Bright SCIdea final and, with it, the pivotal presentation in front of a live audience and panel of expert judges.
Many of us take it as a given that we speak to people at work in our native tongue. The nuances of communication – the cultural subtleties and oddities of the English language – aren’t a concern. But Team Eolic Wall had to present in their second language.
‘This was not our first international presentation, but it was the first one in a foreign language,’ said Alfredo Calle, Eolic Wall founder, ‘so that's always a little bit intimidating until one gets used to it.’
The key to them nailing the pitch was in the spade-work. Calle and his colleagues rehearsed the speech until they knew it by heart. ‘It’s all about training and preparation,’ he said. ‘The more you rehearse, the more confident you feel when the presentation moment comes.’
Of course, the presentation is predictable but the judges’ questions are less so. Having undergone the rigours of competition, Calle recommends that this year’s entrants prepare by trying to predict the types of questions they will be asked. A cold rehearsal could help with the potentially stunning situation of someone throwing questions at you from strange angles.
That team Eolic Wall presented its technology online made theirs even trickier still, especially given a technical hitch at the beginning. But they had polished the presentation to a smoothness that offset such difficulties and came away as joint winners of the Audience Award.
The only lingering regret for them was that Covid prevented them from coming to London. ‘We wish we could have made it to the final,’ he said. ‘Facing the judges and audience live would have been a tremendously valuable and enriching experience.’
Since the Bright SCIdea final, the Eolic Wall is being built brick by brick. The team has received three grants in recent months including one from ProCiencia, the largest innovation agency of the Peruvian government.
Eolic Wall's wall-mounted wind turbine is designed to power homes and offices in situ.
However, perhaps the most exciting development is the technology itself. ‘We have accomplished a peripherally supported wind turbine that works with magnetic levitation,’ Calle said. ‘That's a huge milestone that makes us believe we are building something big.’
Calle hopes for more investment to develop the technology further. At heart, he believes the Eolic Wall will give regular people the chance to generate affordable wind energy from home.
‘We are working out a solution to democratise wind energy for the sake of this blue rock we call home.’
>> Find out how Team Eolic Wall’s innovative technology in part 1 of this blog.
Imagine owning a small wind turbine that generates all of your home’s energy needs. As the clock counts down on entries for for the 2023 Bright SCIdea Challenge, we caught up with Team Eolic Wall, the Audience Winner for the 2022 competition.
Eolic Wall was always a nice fit for Bright SCIdea. The team spotted a problem in our renewable energy mix and came up with a scientific business idea to solve it. They saw that wind energy is generated for the public, but it isn’t generated by the public. This stands in bright contrast to solar power generation.
‘Today, 40% of all installed capacity in solar energy is based on solar panels installed on the rooftops of home and corporate buildings,’ said Alfredo Calle, founder of Eolic Wall. ‘The remaining 60% correspond to solar farms.’
Eolic Wall's wall-mounted wind turbine is designed to power homes and offices in situ.
The wind industry is different. ‘Only 1% of the installed capacity comes from households and businesses,’ he added. ‘That is, 99% of all installed capacity in the world comes from wind farms. That sort of concentration is a problem that hampers the energy transition.’
Calle believes this disparity hampers the move from fossil fuel dependency to clean, renewable energy. For many, micro-generation is key. We need to put power – renewable power – in the hands of the people. His idea is to make wind energy available in the home, just as solar exists on roofs everywhere.
The scale of this task is daunting. It turns out there’s a reason why we don’t all have wind turbines bolted onto our homes. The problem, Calle argues, is that a windmill must be large to be efficient.
He believes the Eolic Wall could change that – that this wall-mounted wind turbine is efficient enough to power our homes and offices.
‘We have created a technology that not only doubles wind speed to harvest more power from the same wind resources, but also has a wind turbine that works with magnetic levitation to almost eliminate any friction.’
So, how did a team based out of the National University of Engineering in Peru and Universidade Estadual Paulista in Brazil end up competing for the £5,000 first prize in the Bright SCIdea final?
Chance. Fortune. Happenstance. Calle and his colleagues came upon Bright SCIdea through a social media post that immediately captured their attention.
‘We thought that the Eolic Wall was ideal for Bright SCIdea because of the huge positive impact that this technology could have,’ he said, ‘and also because it perfectly fit into Bright SCIdea’s thesis of supporting ideas in the intersection of business, innovation and science.’
Applying was simple, although the business plan submission was intimidating at first. However, like all BrightSCIdea applicants they received coaching, and their brainchild found form.
‘The key driver to overcome that challenge was not to miss any training sessions and tutorials,’ Calle said. ‘The good news is that after going through the whole process you feel that everything was worthwhile. No pain, no gain.’
Check out fellow 2022 finalist Klara Hatinova from Team Happy BioPatch in conversation with the Periodic Fable podcast.
An Artificial Intelligence tool that could change the way we treat heart disease wowed the judges at this year’s Bright SCIdea competition. Now that the dust has settled, we asked Raphael Peralta, from the winning CardiaTec team, about winning the competition, the need for this technology, and tips for future participants. After winning this prestigious competition and coming away with the £5,000 first prize, the future is bright for co-founders Raphael Peralta, Thelma Zablocki and Namshik Han. So, how do they reflect on the story so far?
Team CardiaTec (UK)
Tell us about CardiaTec
Cardiovascular disease is the world’s leading cause of death, and affects countless lives. Despite this, investment and innovation within the space has been severely stagnated, especially in comparison to fields such as oncology. The current treatment landscape remains unchanged, and treatments are most often prescribed in a standardised, one-size-fits-all approach. However, people are fundamentally different, and as shown by the Covid-19 pandemic, similar groups of people can experience a disease in a significantly different manner, and as such it is very important to understand biological processes at a patient level to produce effective therapeutic outcomes.
CardiaTec is leveraging artificial intelligence to structure and analyze large scale biological data that spans the full multiomic domain. This allows for a comprehensive understanding of disease pathophysiology to better develop novel and effective therapeutics for cardiovascular disease.
Casting your mind back to the moment you were announced the winner of Bright SCIdea 2020, what were your initial thoughts?
We thought we had a good opportunity to win it, but obviously when it was announced, it was a great feeling. Winning this competition is a further validation that what we are generating has real world value.
It was a great judging panel, with a breadth of experience across drug discovery and the pharmaceutical industry. We were up against immense global competition and the fact that we won shows that there’s a need for novel innovation in the cardiovascular space to ultimately drive the development of new therapeutics that are going to help change people's lives.
How did you think of the idea? Was there a ‘eureka’ moment?
The way the initial idea came about was through the identification that the cardiovascular space had a massive unmet need compared to other spaces such as oncology. I had worked with a cardiovascular company doing some consulting work and this is where it came to light.
In combination, multiomic techniques are becoming increasingly accessible in line with technological developments, which have made processes of next generation sequencing and proteomic profiling increasingly cheaper. These processes generate large amounts of data, which then lend themselves to applications of machine learning to derive biologically meaningful insights. These process, although becoming increasingly familiar in areas such as oncology, are highly underrepresented in cardiovascular disease, and thus there spans opportunity to develop completely unique and novel insights.
How does the technology work?
Here, CardiaTec uses data across genomics, epigenomics, transcriptomics, proteomics, and metabolomics, to generate novel biological insights with the help of AI and machine learning applications. Taking these many ‘omics’ into consideration is what defines a ‘multiomic’ approach. Biology is complex, and trends require full multiomic assessment to truly understand where dysregulation of specific processes is occurring, to then inform the best means of intervention.
CardiaTec is developing a platform, which with time will grow to become one of the most comprehensive foundations of cardiovascular disease biology. Results and outcomes are iteratively incorporated into the model, and new hypotheses are tried and tested across a range of pre-clinical settings. Collectively, CardiaTec aims to generate novel drug targets that can be used to help reduce the burden of disease in current and future patient population.
In the process of getting to the final, there were several opportunities to engage with entrepreneurs, investors, business leaders, and experts in intellectual property (IP). Can you share key takeaways from these sessions?
One of the most important things you can do is speak to people. Every business starts from an idea. As you start developing, you change and refine the business model. We take every chance to engage with people who have industry experience. It’s really important that we take the advice of these people on board; this is especially true in the field of biotechnology where you take risks across the technology side, the commercial side, and the biological side. It takes a lot of experience to mitigate those risks.
How difficult has it been taking that idea and turning it into a viable business proposition?
Thelma and I came out of the MPhil in Bioscience Enterprise at the University of Cambridge. It gave us this really strong foundation to start building. We also had the biological knowledge from our previous degrees. This framework, where we had key opinion leaders and great people in the field with whom we could bounce ideas off, was the first step. We saw that the idea was really positive and was received well by a lot of people. So, we thought: ‘we’re onto something’.
When building a biotech company, if you’re not passionate about it and don’t want to spend a lot of your time dedicated to the project, then it’s not going to take off. You need to be there to make changes, and really embrace and understand where you believe it’s going to go in line with the advice you've been given and the insights that you have generated.
We’re not only interested in understanding the intricate nature of biology. We’re also interested in how this has real life application in changing people’s lives. Every person we speak to has been affected in some way by cardiovascular disease.
I noticed that your presentation was really polished. Do you have any tips for people presenting in the final?
We’ve presented a lot of times so I think practice makes perfect. With a presentation, you need to be able to tell a story. It’s all about the storyline and building that image. You have to take care and be diligent in the process. Take time to make sure everything is structured correctly and that the story flows. Don’t be afraid to present to a lot of people who will give you advice. Take the time to make the amendments and run it through again and again, and see what the response is. So, take your time on the presentation to get your story across.
You were both very calm when the judges’ questions came. How did you prepare for these questions?
Out of this Cambridge network, the people we spoke to all asked the right questions. You see the pattern of these questions. They all want to know similar things. So, once we identified that pattern, we wrote down the questions that were important from our conversations and we practiced responses to these questions, which were by this point, fully embedded into the company’s business model; which then lends itself to an insightful, actionable response.
How are you going to use the £5,000 prize money and what’s next?
We’ll put the prize money towards refining of some of our technology. In terms of what’s next, Thelma (Zablocki), Namshik (Han), and I are dedicated to this company. We want to see it through and eventually make a drug that ends up reaching patients. This will take a long time.
To see that in the real world, where someone’s getting prescribed a drug that you discovered would be incredible.
>> For more on this year’s Bright SCIdea final, go to: https://www.soci.org/news/2022/3/bright-scidea-final-2022.